Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer

Programmed cell death protein (PD-1) is an important immunosuppressive molecule, which can inhibit interaction between PD-1 and its ligand PD-L1, further enhancing the T cell response and anti-tumor activity, which is called immune checkpoint blockade. Immunotherapy, represented by immune checkpoint...

Full description

Bibliographic Details
Main Authors:	Liting Sun, Cong Meng, Xiao Zhang, Jiale Gao, Pengyu Wei, Jie Zhang, Zhongtao Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Pharmacology
Subjects:	colorectal cancer immunotherapy PD-1/PD-L1 inhibitors immune-related adverse events prediction
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1167670/full

Similar Items

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
by: Ugochi Ebinama, et al.
Published: (2023-11-01)

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
by: Zhengyang Yang, et al.
Published: (2022-09-01)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2021-11-01)

Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors  Based Combination Therapy
by: Xiaoyu GUO, et al.
Published: (2021-07-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022-03-01)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
by: Qingyang Lei, et al.
Published: (2020-07-01)

Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
by: Yuegang Li, et al.
Published: (2022-10-01)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
by: André F. Oliveira, et al.
Published: (2019-05-01)

Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system
by: Hongxia Shi, et al.
Published: (2024-04-01)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
by: Janina Świderska, et al.
Published: (2021-12-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
by: Peng-Fei Wang, et al.
Published: (2017-10-01)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2022-11-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
by: Peng Ding, et al.
Published: (2023-05-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
by: Lina María Serna-Higuita, et al.
Published: (2021-12-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
by: Hoda Z. Pourhassan, et al.
Published: (2019-09-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers
by: Qiping Jiang, et al.
Published: (2024-01-01)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
by: Luisa Maria Griewing, et al.
Published: (2021-03-01)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
by: Chaoyue Su, et al.
Published: (2020-09-01)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
by: Liping Pei, et al.
Published: (2023-02-01)

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
by: Alessio Cortellini, et al.
Published: (2019-11-01)

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
by: Yanhao Liu, et al.
Published: (2022-04-01)

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
by: Adam Mor, et al.
Published: (2022-01-01)

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
by: Yinjun He, et al.
Published: (2023-01-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
by: Kim A. Brogden, et al.
Published: (2018-02-01)

Is a triggering role or a causative role of PD-1/PDL-1 inhibitors in the development of paraneoplastic dermatomyositis?
by: Michela Starace, et al.
Published: (2022-07-01)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
by: Melissa L. Bastacky, et al.
Published: (2021-11-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy
by: Fengling Wang, et al.
Published: (2021-03-01)

Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events
by: Matin Dokht Ashoori, et al.
Published: (2021-01-01)